Gammaretroviral production and T cell transduction to genetically retarget primary T cells against cancer

Gongbo Li, Kyungho Park, Marco L. Davila*

*Corresponding author for this work

Research output: Chapter in Book/Report/Conference proceedingChapter

10 Scopus citations


Adoptive T cell therapy has demonstrated tremendous outcomes against treatment-refractory leukemias and solid tumor malignancies. As opposed to industry-developed drugs that are manufactured and dispensed to hospitals and/or patients, T cells are produced in academic laboratories for clinical research and are a highly personalized therapy that represents a “living drug.” The technology behind genetic modification of primary T cells has been developed and refined by a few academic medical centers. We anticipate that the exciting results generated by these efforts will lead to further investigation by other academic and industry institutions. To facilitate this adaptation we present optimized protocols for gammaretroviral production, T cell isolation, and genetic modification to create gene-targeted T cells.

Original languageEnglish (US)
Title of host publicationMethods in Molecular Biology
PublisherHumana Press Inc.
Number of pages8
StatePublished - 2017
Externally publishedYes

Publication series

NameMethods in Molecular Biology
ISSN (Print)1064-3745


  • Adoptive cell therapy
  • Chimeric antigen receptor
  • Immunotherapy
  • Retroviral vector transduction
  • T cell

ASJC Scopus subject areas

  • Molecular Biology
  • Genetics


Dive into the research topics of 'Gammaretroviral production and T cell transduction to genetically retarget primary T cells against cancer'. Together they form a unique fingerprint.

Cite this